1800 M STREET, NW
SUITE 1000
WASHINGTON,
DC
20036-5807
202.778.1822
202.822.8106 fax
|
Andrew Goldfarb's practice focuses on complex civil litigation, bankruptcy litigation, food and drug law, internal investigations, and criminal defense. At Zuckerman Spaeder LLP, Mr. Goldfarb has represented post-confirmation bankruptcy trustees in actions seeking recoveries for unsecured creditors of major retailers; counseled and defended a data vendor affected by a potential data breach arising out of a computer theft; conducted an independent internal investigation for a major pharmaceutical company; and defended an individual in a criminal prosecution relating to the alleged promotion of fraudulent tax shelters by a major accounting firm.
In addition, in the first case involving the generic exclusivity forfeiture provisions of the Federal Food, Drug and Cosmetic Act, Mr. Goldfarb helped a generic drug manufacturer defeat an action for a temporary restraining order, allowing it to remain on the market. Mr. Goldfarb also co-authored an amicus brief on behalf of tobacco control and public health organization in a Supreme Court case relating to the imposition of punitive damages on a tobacco company.
Prior to joining Zuckerman Spaeder, Mr. Goldfarb was a trial attorney for six years in the Civil Division of the United States Department of Justice. During this time, he served on the Tobacco Litigation Team, which prosecuted the United States' civil RICO enforcement action against the tobacco industry. Mr. Goldfarb was a key part of the government’s trial team during the nine-month trial, and delivered part of the government's closing argument. In August 2006, the federal district court issued a 1650-page opinion finding the defendants liable for RICO violations and ordered injunctive relief.
Mr. Goldfarb also spent four years as an associate at Fox, Bennett & Turner, a food and drug law firm in Washington, D.C., and was a senior associate at The Neas Group, a strategic consulting firm.
Experience
-
Represented the post-confirmation committee in a bankruptcy suit to recover funds on behalf of creditors from private equity investor on deepening insolvency and other theories.
-
Represented a generic drug manufacturer when it prevailed in defeating a motion for a preliminary injunction seeking to stop FDA from approving its generic.
-
Litigated the claims of a retail company against its outside law firms, auditors, and certain directors and officers for alleged malpractice in connection with the demise and bankruptcy of the company.
-
Currently representing the lead defendant in the Southern District of New York’s prosecution of former partners of Ernst & Young and others for allegedly promoting fraudulent tax shelters.
-
Conducted an internal investigation on behalf of an international pharmaceutical company that had failed to disclose a preliminary report of a safety study to the FDA before an important advisory committee meeting.
EDUCATION
-
Georgetown University Law Center,
J.D.,
1995
-
Harvard University,
A.B.,
1990, magna cum laude
COURT ADMISSIONS
- U.S. District Court, District of Columbia
BAR ADMISSIONS
- District of Columbia
- New York
- California
|
PRACTICES
Related Information
|